Insulin therapy for diabetes mellitus: Treatment regimens and associated costs

Diabetes and Metabolism

Volumn 38, Issue 2, 2012, Pages 156-163

  Charbonnel, B ^a   Penfornis, A ^b   Varroud Vial, M ^c   Kusnik Joinville, O ^d   Detournay, B ^d  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^d CEMKA EVAL   (France)

Author keywords

Diabetes mellitus; Drug costs; Epidemiology; France; Insulin; Statistics and numerical data; Therapy

Indexed keywords

INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LONG ACTING INSULIN; SHORT ACTING INSULIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; DIABETES MELLITUS; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DRUG COST; FEMALE; FRANCE; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHARMACIST; PRESCRIPTION; PROFESSIONAL PRACTICE; SELF INJECTION; SELF MONITORING; SINGLE DRUG DOSE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BLOOD GLUCOSE SELF-MONITORING; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG COSTS; FEMALE; FRANCE; HEALTH CARE COSTS; HOUSE CALLS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PATIENT PREFERENCE; QUESTIONNAIRES; YOUNG ADULT;

EID: 84859708823     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2011.10.003     Document Type: Article

References (21)

1. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
2. Kusnik-Joinville O., Salanave A.W., Ricordeau B., Allemand P.H. Diabète traité: quelles évolutions entre 2000 et 2005 ?. Prat Organ Soins 2007, 38:1-12.
3. Kusnik-Joinville O., Weill A., Ricordeau P., Allemand H. Diabète traité en France en 2007: un taux de prévalence proche de 4 % et des disparités géographiques croissantes. Bull Epidemiol Hebd 2008, 43:409-413.
4. Ricci P., Blotière P.O., Weill A., Simon D., Tuppin P., Ricordeau P., et al. Diabète traité en France: quelles évolutions entre 2000 et 2009 ?. Bull Epidemiol Hebd 2010, 42-43:425-431.
5. Bringer J., Fontaine P., Detournay B., Nachit-Ouinekh F., Brami G., Eschwege E. Prevalence of diagnosed type 2 diabetes mellitus in the French general population: the INSTANT study. Diabetes Metab 2009, 35:25-31.
6. Traitement médicamenteux du diabète de type 2 (Actualisation). Novembre 2006. Recommandation de bonne pratique (synthèse, recommandation et argumentaire). Diabetes Metab 2007, 33:S1-S105. AFSSAPS-HAS., Recommandation Professionnelle.
7. Robert J., Roudier C., Poutignat N., Fagot-Campagna A., Weill A., Rudnichi A., et al. Prise en charge des personnes diabétiques de type 2 en France en 2007 et tendances par rapport à 2001. Bull Epidemiol Hebd 2009, 42-43:455-460.
8. Singh S.R., Ahmad F., Lal A., Yu C., Bai Z., Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009, 17:385-397.
9. Giugliano D., Maiorino M.I., Bellastella G., Chiodini P., Ceriello A., Esposito K. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 2011, 34:510-517.
10. Charbonnel B., Balarac N., Cazeneuve B., Augendre-Ferrante B., Le Thai F., Drouin P. Which are the insulin treatment regimens used in France? The "Schema survey" Diabetes Metab 2001, 27:591-597.
11. Varroud-Vial M., Guerci B., Attali C., Simon D., Detournay B., Halimi S., et al. Prise en charge du diabète en France: des progrès certains. Res Diabete 2007, 31:4-9.
12. Detournay B. Aspects épidémiologiques et économiques de l'insulinothérapie en France métropolitaine. Med Mal Metabol 2008, Suppl. 2:S149-S152.
13. Fagot-Campagna A., Fosse S., Roudier C., Romon I., Penfornis A., Lecomte P., et al. Characteristics, vascular risk and complications in people with diabetes, in metropolitan France: major improvements between ENTRED 2001 and ENTRED 2007 studies. Bull Epidemiol Hebd 2009, 42-43:450-455.
14. Robert J., Roudier C., Poutignat N., Fagot-Campagna A., Weill A., Rudnichi A., et al. Health care of persons with type 2 diabetes in France in 2007 and trends compared to 2001. Bull Epidemiol Hebd 2009, 42-43:455-460.
15. Detournay B., Raccah D., Cadilhac M., Eschwège E. Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab 2005, 31:S1-S18.
16. Romon I., Fosse S., Eschwège E., Simon D., Weill A., Varroud-Vial M., et al. Prevalence of macrovascular complications and cardiovascular risk factors in people treated for diabetes and living in France. The ENTRED study 2001. Diabetes Metab 2008, 34:140-147.
17. Maddigan S.L., Feeny D.H., Majumdar S.R., Farris K.B., Johnson J.A. Understanding the determinants of health for people with type 2 diabetes. Am J Public Health 2006, 96:1649-1655.
18. Ng E., Dasgupta K., Johnson J.A. An algorithm to differentiate diabetic respondents in the Canadian Community Health Survey. Heath Reports Statistics Canada 2008, 19:1-9.
19. Available on line on and http://www.ameli.fr/.
20. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
21. Ricci P., Chantry M., Detournay B., Poutignat N., Kusnik-Joinville O., Raimond V., et al. Coût des soins remboursés par l'Assurance maladie aux personnes traitées pour diabète: études Entred 2001 et 2007. Bull Epidemiol Hebd 2009, 42-43:464-469.